Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jul;71(7):1453-1454.
doi: 10.1136/gutjnl-2021-326313. Epub 2021 Oct 27.

Reply to: Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?

Michael Pavlides  1   2   3 , Ferenc E Mózes  4 , Stephen A Harrison  4
Affiliations
Comment

Reply to: Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?

Michael Pavlides et al. Gut. 2022 Jul.
No abstract available

Keywords: fatty liver; hepatocellular carcinoma; liver cirrhosis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: MP is shareholder in Perspectum Ltd. SAH has research grants from Akero, Axcella, Cirius, CiVi Biopharma, Cymabay, Galectin, Galmed, Genfit, Gilead Sciences, Hepion Pharmaceuticals, Hightide Therapeutics, Intercept, Madrigal, Metacrine, NGM Bio, Northsea Therapeutics, Novartis, Novo Nordisk, Poxel, Sagimet, Viking. He has received consulting fees from Akero, Altimmune, Alentis, Arrowhead, Axcella, Canfite, Cirius, CiVi, Cymabay, Echosens, Enyo, Fibronostics, Foresite Labs, Fortress Biotech, Galectin, Genfit, Gilead Sciences, Hepion, HIghtide, HistoIndex, Intercept, Kowa, Madrigal, Metacrine, NGM, Northsea, Novartis, Novo Nordisk, Poxel, Prometic, Ridgeline, Sagimet, Terns, and Viking.

Comment on

References

    1. Majumdar A, Tsochatzis EA. Non-Invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back? Gut 2022;71:1236–7. 10.1136/gutjnl-2021-325994 - DOI - PubMed
    1. Mózes FE, Lee JA, Selvaraj EA, et al. . Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut 2022;71:1006–19. 10.1136/gutjnl-2021-324243 - DOI - PMC - PubMed
    1. Dioguardi Burgio M, Sartoris R, Beaufrere A, et al. . Liver surface nodularity on non-contrast MRI identifies advanced fibrosis in patients with NAFLD. Eur Radiol 2021. doi:10.1007/s00330-021-08261-6. [Epub ahead of print: 17 Sep 2021]. - DOI - PubMed
    1. de Franchis R, Baveno VI Faculty . Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015;63:743–52. 10.1016/j.jhep.2015.05.022 - DOI - PubMed
    1. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver Galle PR, Forner A, Llovet JM. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182–236. 10.1016/j.jhep.2018.03.019 - DOI - PubMed

MeSH terms